Allarity Therapeutics CFO resigns; appoints Jeffrey Ervin as part-time CFO effective July 1, 2025

Allarity Therapeutics, Inc.

CFO Alexander Epshinsky resigned June 30, 2025; not due to any disagreement with the company.
Jeffrey S. Ervin appointed part-time CFO on July 1, 2025; annual base salary of $175,000.
Ervin previously served as fractional co-CFO of DDC Enterprise (NYSE: DDC) and chairman/CEO of IMAC Holdings (Nasdaq: BACK).
Ervin also serves as independent director of Cingulate, Inc. (Nasdaq: CING); holds MBA from Vanderbilt.
Severance: 6 months' base salary if terminated after Change-of-Control, subject to signed release.

item 5.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.